Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The urine tumor deoxyribonucleic acid (DNA) testing market has experienced substantial expansion in recent years. It is forecast to grow from $1.18 billion in 2025 to $1.36 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.6%. The historical surge in this market can be attributed to various factors, including the increasing incidence of urinary cancers, the adoption of pcr-based urine testing, advancements in sequencing technologies, a growing awareness of early cancer detection, and the expansion of hospital diagnostic facilities.
The urine tumor deoxyribonucleic acid (DNA) testing market size is poised for significant expansion in the foreseeable future. This market is expected to expand to $2.36 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 14.9%. The projected growth can be attributed to several factors such as AI-driven urine DNA analysis, the development of multiplex and high-throughput assays, the broadening scope of personalized medicine, integration with electronic health records, and an increasing demand for non-invasive monitoring solutions. Key trends anticipated during this period include non-invasive cancer monitoring, advancements in liquid biopsy, AI-powered genetic analysis, high-sensitivity urine DNA detection, and the integration of these systems with clinical decision support systems.
Get A Free Sample Report With In-Depth Market Insights:
Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Industry Drivers: What’s Behind The Revenue Growth?
The rising prevalence of urological cancers is projected to fuel the expansion of the urine tumor deoxyribonucleic acid (DNA) testing market in the upcoming years. These cancers affect the urinary system and male reproductive organs, specifically the kidneys, bladder, prostate, and testes, with their occurrence primarily increasing due to aging demographics, given that cancer risk escalates with advancing age. Urine tumor DNA testing plays a crucial role in managing urological cancers by enabling the non-invasive identification of cancer-specific genetic mutations in urine, thereby facilitating prompt diagnosis, continuous disease monitoring, and tailored treatment planning. As an example, in December 2025, Cancer Australia, an Australia-based government department, noted an estimated 28,868 new prostate cancer cases were diagnosed, accounting for approximately 30% of all new cancer diagnoses among men. Consequently, the growing incidence of urological cancers is anticipated to propel the demand for urine tumor deoxyribonucleic acid (DNA) testing.
Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Segment Outlook: Which Categories Are Growing Fastest?
The urine tumor deoxyribonucleic acid (DNA) testing market covered in this report is segmented –
1) By Technology: Polymerase Chain Reaction-based, Next-Generation Sequencing, Other technologies
2) By Product Type: Assay Kits, Instruments, Services
3) By Cancer Type: Bladder Cancer, Prostate Cancer, Kidney Cancer, Other Cancer Types
4) By Sample Type: First-Morning Urine, Random Urine Samples, Catheterized Urine Samples
5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users
Subsegments:
1) By Polymerase Chain Reaction Based: Real Time Polymerase Chain Reaction, Digital Polymerase Chain Reaction, Multiplex Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction
2) By Next Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Transcriptome Sequencing
3) By Other Technologies: Microarray Based Testing, Hybridization Based Assays, Mass Spectrometry Based Analysis, Fluorescence In Situ Hybridization
#Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies in the urine tumor deoxyribonucleic acid (DNA) testing market are increasingly concentrating on developing advanced solutions, such as urine-based liquid biopsy platforms, to facilitate non-invasive cancer detection, improve diagnostic accuracy, and support personalized treatment planning. These urine-based liquid biopsy platforms are non-invasive diagnostic systems engineered to detect and analyze tumor-derived DNA and other biomarkers from urine samples for cancer identification, monitoring, and assessment of disease progression. For instance, in September 2024, PreAnalytiX, a joint venture between QIAGEN, a Netherlands-based sample-to-insight provider, and Becton, Dickinson and Company, a US-based medical technology firm, introduced a novel urine-based liquid biopsy solution designed to enable high-quality DNA stabilization and extraction for subsequent molecular analyses. This platform, developed for both clinical and research applications, features standardized urine collection, efficient DNA preservation, and compatibility with next-generation sequencing workflows, thereby assisting in early cancer detection, accurate biomarker assessment, and enhanced patient management.
Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Competitive Overview And Top Companies
Major companies operating in the urine tumor deoxyribonucleic acid (DNA) testing market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Illumina Inc., QIAGEN N.V., Bio-Techne Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., MDxHealth SA, Biodesix Inc., Sysmex Inostics GmbH, Pacific Edge Limited, Apostle Inc., Lucence Diagnostics, Pangea Laboratory, Nucleix Ltd, Genomica Lab, Vesica Health, Biocept Inc., Promis Diagnostics Inc.
View The Full Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Report:
Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the urine tumor deoxyribonucleic acid (DNA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urine tumor deoxyribonucleic acid (DNA) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
